CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development(1)	[1]	$ 92,035	$ 34,032
Acquired in-process research and development(2)	[2]	0	1,000
Selling, general and administrative		8,704	3,677
Total operating expenses		100,739	38,709
Loss from operations		(100,739)	(38,709)
Other income (expense):
Other income (expense), net		73	9
Total other income (expense), net		73	9
Net loss		(100,666)	(38,700)
Other comprehensive income (loss)
Unrealized gain on available-for-sale securities, net of tax		8	0
Comprehensive loss		$ (100,658)	$ (38,700)
Net loss per share attributable to common stockholders, basic and diluted		$ (0.93)	$ 0
Weighted-average common shares outstanding, basic and diluted		107,869,570	0

[1] Includes related-party amounts of $2,000 and $188 for the three months ended March 31, 2022 and 2021, respectively

[2] Includes related-party amounts of $0 and $1,000 for the three months ended March 31, 2022 and 2021, respectively